Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T‐cell lymphoma

por Foss, Francine, Pro, Barbara, Miles Prince, H., Sokol, Lubomir, Caballero, Dolores, Horwitz, Steven, Coiffier, Bertrand
Publicado 2016

Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial

por Foss, Francine, Horwitz, Steven, Pro, Barbara, Miles Prince, H., Sokol, Lubomir, Balser, Barbara, Wolfson, Julie, Coiffier, Bertrand
Publicado 2017

Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis

por Dimopoulos, Meletios A., Leleu, Xavier, Moreau, Philippe, Richardson, Paul G., Liberati, Anna Marina, Harrison, Simon J., Miles Prince, H., Ocio, Enrique M., Assadourian, Sylvie, Campana, Frank, Malinge, Laure, Sémiond, Dorothée, van de Velde, Helgi, Yong, Kwee
Publicado 2020

P1115: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2

por Walewski, Jan, Min Kim, Tae, Cho, Seok-Goo, Jarque, Isidro, Iskierka-Jażdżewska, Elżbieta, Poon, Michelle, Miles Prince, H., Yong Oh, Sung, Lim, Francesca, Segura, Cecilia Carmen Carpio, Tan, Tran-Der, Ayyappan, Sabarish, Gutiérrez, Antonio, LI, Jingjin, Ufkin, Melanie, Zhu, Min, Chaudhry, Aafia, Mohamed, Hesham, Ambati, Srikanth, Kim, Won-Seog
Publicado 2023

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

por Lesokhin, Alexander M., Tomasson, Michael H., Arnulf, Bertrand, Bahlis, Nizar J., Miles Prince, H., Niesvizky, Ruben, Rodrίguez-Otero, Paula, Martinez-Lopez, Joaquin, Koehne, Guenther, Touzeau, Cyrille, Jethava, Yogesh, Quach, Hang, Depaus, Julien, Yokoyama, Hisayuki, Gabayan, Afshin Eli, Stevens, Don A., Nooka, Ajay K., Manier, Salomon, Raje, Noopur, Iida, Shinsuke, Raab, Marc-Steffen, Searle, Emma, Leip, Eric, Sullivan, Sharon T., Conte, Umberto, Elmeliegy, Mohamed, Czibere, Akos, Viqueira, Andrea, Mohty, Mohamad
Publicado 2023

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX

por Kaufman, Jonathan L., Dimopoulos, Meletios A., White, Darrell, Benboubker, Lotfi, Cook, Gordon, Leiba, Merav, Morton, James, Joy Ho, P., Kim, Kihyun, Takezako, Naoki, Moreau, Philippe, Sutherland, Heather J., Magen, Hila, Iida, Shinsuke, Kim, Jin Seok, Miles Prince, H., Cochrane, Tara, Oriol, Albert, Bahlis, Nizar J., Chari, Ajai, O’Rourke, Lisa, Trivedi, Sonali, Casneuf, Tineke, Krevvata, Maria, Ukropec, Jon, Kobos, Rachel, Avet-Loiseau, Hervé, Usmani, Saad Z., San-Miguel, Jesus
Publicado 2020